Assess whether scientific advice should be sought before the next trial

Situation

The desk packet is complete-response-letter deficiency list after a site-change that invalidates stability claims. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a site-change that invalidates stability claims.

Hypotheses to test

• Complete-response-letter deficiency list reads as Proceed under protocol once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population.
• Complete-response-letter deficiency list is closer to Pause the pathway after a site-change that invalidates stability claims; Proceed under protocol would over-claim this Pharmacovigilance extract.
• Escalate safety review is still live in complete-response-letter deficiency list for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.
• Complete-response-letter deficiency list is missing the fact 505(b)(2) development lead needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether complete-response-letter deficiency list supports the labeled claim 505(b)(2) development lead would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a site-change that invalidates stability claims and write the one fact that would move scientific advice should be for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.